ATRACURIUM Drug Patent Profile
✉ Email this page to a colleague
When do Atracurium patents expire, and when can generic versions of Atracurium launch?
Atracurium is a drug marketed by Baxter Hlthcare, Baxter Hlthcare Corp, Eugia Pharma, Hikma, Hospira, Hospira Inc, Meitheal, Pharmobedient, Teva Parenteral, Watson Pharms Teva, and Watson Labs Inc. and is included in twenty-two NDAs.
The generic ingredient in ATRACURIUM is atracurium besylate. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the atracurium besylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atracurium
A generic version of ATRACURIUM was approved as atracurium besylate by HIKMA on July 18th, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ATRACURIUM?
- What are the global sales for ATRACURIUM?
- What is Average Wholesale Price for ATRACURIUM?
Summary for ATRACURIUM
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 22 |
| DailyMed Link: | ATRACURIUM at DailyMed |

